title: Pergolide mesylate and idiopathic Parkinson disease.
abstract: We studied the effects of pergolide mesylate in an open trial of 23 patients with idiopathic Parkinson disease (PD). All had suffered from loss of efficacy or dose-limiting side effects on current antiparkinsonian regimens. On pergolide therapy, improvement, which was maintained for 6 months, was noted in some parkinsonian features in all 23 patients. All patients suffering from on-off phenomenon were helped by pergolide. Significant side effects were not encountered. Pergolide is useful in the treatment of PD.
mesh_terms: D000293:Adolescent; D000328:Adult; D002230:Carbidopa / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D004338:Drug Combinations / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004873:Ergolines / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide
chemical_list: D004338:Drug Combinations; D004873:Ergolines; C009265:carbidopa, levodopa drug combination; D010479:Pergolide; D007980:Levodopa; D002230:Carbidopa